Home › Immunoglobulin Light-chain Amyloidosis › Massachusetts › Boston
Immunoglobulin Light-chain Amyloidosis clinical trials in Boston, MA
7 studies for Immunoglobulin Light-chain Amyloidosis are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
RecruitingPhase 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Tufts Medical Center, Boston
Teclistamab-Daratumumab in AL Amyloidosis
RecruitingPhase 2
- Boston Medical Center, Boston
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
RecruitingPhase 1/2
- Research Site, Boston
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
RecruitingPhase 3
- Boston Medical Center, Boston
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
RecruitingObservational study
- Boston University Cancer Research Center, Boston
Molecular Imaging of Primary Amyloid Cardiomyopathy
Recruiting
- Brigham and Womens' Hospital, Boston
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
RecruitingObservational study
- Tufts Medical Center, Boston
Immunoglobulin Light-chain Amyloidosis trials in other cities
- Rochester, MN5 studies
- Durham, NC4 studies
- New York City, NY4 studies
- Cleveland, OH3 studies
- Columbus, OH3 studies
Other studies in Boston
- Breast Cancer112 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)85 studies
- Metastatic Cancer63 studies
- Colorectal Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.